A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).

Authors

Desamparados Roda

The Institute of Cancer Research and The Royal Marsden, London, United Kingdom

Desamparados Roda , Yvette Drew , Analia Azaro , Alan David Smith , Alastair Greystoke , Elisabet Sicart , Pablo V. Escriba , Xavier Busquets , Victoria LLado , Vicente Tur , Edwin Klumper , Jordi Rodon Ahnert , L Rhoda Molife , Ruth Plummer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.

First Author: Ben George

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.

First Author: John Sarantopoulos

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.

First Author: Mark N. Stein

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

A dose escalation, single arm, phase Ib-II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme.

First Author: Mohamad Adham Salkeni